335 related articles for article (PubMed ID: 32102485)
21. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
22. Gene Transactivation and Transrepression in MYC-Driven Cancers.
Scafuro M; Capasso L; Carafa V; Altucci L; Nebbioso A
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801599
[No Abstract] [Full Text] [Related]
23. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
24. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
25. Cancer: negative feedback for B cells.
Staudt LM
Nature; 2004 Oct; 431(7011):919-20. PubMed ID: 15496906
[No Abstract] [Full Text] [Related]
26. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis.
Link JM; Hurlin PJ
Biochim Biophys Acta; 2015 May; 1849(5):554-62. PubMed ID: 24731854
[TBL] [Abstract][Full Text] [Related]
27. Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc.
D'Artista L; Bisso A; Piontini A; Doni M; Verrecchia A; Kress TR; Morelli MJ; Del Sal G; Amati B; Campaner S
Oncotarget; 2016 Apr; 7(16):21786-98. PubMed ID: 26943576
[TBL] [Abstract][Full Text] [Related]
28. EBV latent membrane protein 2A orchestrates p27
Fish K; Sora RP; Schaller SJ; Longnecker R; Ikeda M
Blood; 2017 Dec; 130(23):2516-2526. PubMed ID: 29074502
[TBL] [Abstract][Full Text] [Related]
29. Impact of c-MYC expression on proliferation, differentiation, and risk of neoplastic transformation of human mesenchymal stromal cells.
Melnik S; Werth N; Boeuf S; Hahn EM; Gotterbarm T; Anton M; Richter W
Stem Cell Res Ther; 2019 Mar; 10(1):73. PubMed ID: 30836996
[TBL] [Abstract][Full Text] [Related]
30. Human B-lymphocyte precursors do not express the N-myc gene.
Wetherall NT; Vogler LB
Pathobiology; 1992; 60(2):87-92. PubMed ID: 1571096
[TBL] [Abstract][Full Text] [Related]
31. MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes.
Sullivan DK; Deutzmann A; Yarbrough J; Krishnan MS; Gouw AM; Bellovin DI; Adam SJ; Liefwalker DF; Dhanasekaran R; Felsher DW
Oncogene; 2022 Nov; 41(45):4960-4970. PubMed ID: 36207533
[TBL] [Abstract][Full Text] [Related]
32. A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas.
Ryan RJH; Petrovic J; Rausch DM; Zhou Y; Lareau CA; Kluk MJ; Christie AL; Lee WY; Tarjan DR; Guo B; Donohue LKH; Gillespie SM; Nardi V; Hochberg EP; Blacklow SC; Weinstock DM; Faryabi RB; Bernstein BE; Aster JC; Pear WS
Cell Rep; 2017 Oct; 21(3):784-797. PubMed ID: 29045844
[TBL] [Abstract][Full Text] [Related]
33. Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma.
Scherger AK; Al-Maarri M; Maurer HC; Schick M; Maurer S; Öllinger R; Gonzalez-Menendez I; Martella M; Thaler M; Pechloff K; Steiger K; Sander S; Ruland J; Rad R; Quintanilla-Martinez L; Wunderlich FT; Rose-John S; Keller U
JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391340
[TBL] [Abstract][Full Text] [Related]
34. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic MYC amplifies mitotic perturbations.
Littler S; Sloss O; Geary B; Pierce A; Whetton AD; Taylor SS
Open Biol; 2019 Aug; 9(8):190136. PubMed ID: 31455158
[TBL] [Abstract][Full Text] [Related]
36. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
37. Crosstalk Between MYC and lncRNAs in Hematological Malignancies.
Arman K; Möröy T
Front Oncol; 2020; 10():579940. PubMed ID: 33134177
[TBL] [Abstract][Full Text] [Related]
38. The role of the proto-oncogene c-myc in B lymphocyte differentiation.
Fernandez D; Sanchez-Arevalo VJ; de Alboran IM
Crit Rev Immunol; 2012; 32(4):321-34. PubMed ID: 23237508
[TBL] [Abstract][Full Text] [Related]
39. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
40. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
